Company Overview of Advaxis, Inc.
Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States. The Lm-LLO immunotherapy platform technology stimulates the immune system to induce antigen-specific anti-tumor immune responses involving innate and adaptive arms of the immune system by inhibiting the T-cells, tregs, and myeloid-derived suppressor cells, and MDSC to promote immunologic tolerance of cancer cells in the tumor. Its lead product ADXS-HPV, an Lm-LLO immunotherapy product candidate used for the treatment of human papilloma virus (HPV) associated cancers, completed its Phase II study. The company is also develop...
305 College Road East
Princeton, NJ 08540
Founded in 2002
Key Executives for Advaxis, Inc.
Chief Executive Officer, President and Director
Total Annual Compensation: $398.8K
Chief Operating Officer and Executive Vice President
Total Annual Compensation: $285.0K
Chief Scientific Officer and Executive Vice President
Total Annual Compensation: $331.2K
Compensation as of Fiscal Year 2014.
Advaxis, Inc. Key Developments
Advaxis, Inc. Presents Preliminary Data from a Phase 1/2 Trial of ADXS-HPV
Mar 16 15
Advaxis, Inc. presented preliminary data from the Phase 1/2 clinical study of its lead immunotherapy product candidate, ADXS-HPV (ADXS11-001), in 10 patients with HPV-associated locally advanced anal cancer indicating that all patients who have completed treatment in the study have had a complete response with no
evidence of recurrence to date (follow-up ranging from 0.5 â “ 24 months). The preliminary data also show that the investigational immunotherapy was well tolerated by the treated patients, and all treatment-related toxicities were within 24 hours of dosing, the most frequent of which include chills/rigors, fever and nausea. The data were highlighted in an oral presentation by Kimberly Perez, M.D., Assistant Professor of Medicine at the Alpert Medical School, Brown University, during the recent International Anal Neoplasia Society (IANS) Scientific Meeting 2015, in Atlanta, Georgia.
Advaxis, Inc. Presents at 25th Annual Institutional Investor Conference, Mar-19-2015 09:05 AM
Mar 10 15
Advaxis, Inc. Presents at 25th Annual Institutional Investor Conference, Mar-19-2015 09:05 AM. Venue: The University Club, 1 W 54th St, New York, NY 10019, United States.
Advaxis, Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-04-2015 10:00 AM
Mar 2 15
Advaxis, Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-04-2015 10:00 AM. Venue: The Boston Marriott Copley Place, Boston, Massachusetts, United States. Speakers: Daniel J. O'Connor, Chief Executive Officer, President and Director.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|